NO20084487L - Fremgangsmater for behandling av nyreforstyrrelser - Google Patents

Fremgangsmater for behandling av nyreforstyrrelser

Info

Publication number
NO20084487L
NO20084487L NO20084487A NO20084487A NO20084487L NO 20084487 L NO20084487 L NO 20084487L NO 20084487 A NO20084487 A NO 20084487A NO 20084487 A NO20084487 A NO 20084487A NO 20084487 L NO20084487 L NO 20084487L
Authority
NO
Norway
Prior art keywords
procedures
treatment
subject
kidney disorders
vegfragonists
Prior art date
Application number
NO20084487A
Other languages
English (en)
Inventor
Napoleone Ferrara
Hans-Peter Gerber
Megan Baldwin
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of NO20084487L publication Critical patent/NO20084487L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)

Abstract

Sammendrag Det tilveiebringes fremgangsmåter for behandling av nyreforstyrrelser hos et individ ved tilførsel av en effektiv mengde av VEGFRagonist, for eksempel en Fltl-agonist, til et individ, Agonistene er sammensatt av sammensetninger som omfatter VEGFRagonister, for eksempel VEGF, antistoffer som er rettet mot Fltl, Fltl-ligander, småmolekylaktivatorer av Fitl eller selektive midler for Fltli en farmasøytisk akseptabel bærer for anvendelse ved aktivering av Fit l.
NO20084487A 2006-03-27 2008-10-24 Fremgangsmater for behandling av nyreforstyrrelser NO20084487L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78624606P 2006-03-27 2006-03-27
PCT/US2007/064950 WO2007112364A1 (en) 2006-03-27 2007-03-26 Methods for treating kidney disorders

Publications (1)

Publication Number Publication Date
NO20084487L true NO20084487L (no) 2008-12-22

Family

ID=38283903

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084487A NO20084487L (no) 2006-03-27 2008-10-24 Fremgangsmater for behandling av nyreforstyrrelser

Country Status (13)

Country Link
US (2) US20070264259A1 (no)
EP (1) EP2015768A1 (no)
JP (1) JP2009541207A (no)
KR (1) KR20080108570A (no)
CN (1) CN101454018A (no)
AU (1) AU2007230580A1 (no)
BR (1) BRPI0709411A2 (no)
CA (1) CA2647268A1 (no)
IL (1) IL194373A0 (no)
MX (1) MX2008012276A (no)
NO (1) NO20084487L (no)
RU (1) RU2008142374A (no)
WO (1) WO2007112364A1 (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210330745A1 (en) * 2018-09-11 2021-10-28 The Texas A&M University System Modulating renal lymphatics to regulate blood pressure
CN112592974A (zh) * 2019-12-13 2021-04-02 四川省人民医院 用于诊断或辅助诊断肾功能不全或肾损伤的诊断剂、试剂盒和应用
TW202130350A (zh) 2019-12-17 2021-08-16 美商奇努克治療美國公司 用阿曲生坦（ＡＴＲＡＳＥＮＴＡＮ）治療ＩｇＡ腎病的方法
CN114720700A (zh) * 2022-05-07 2022-07-08 浙江大学 检测抗细胞骨架相关蛋白4-IgG自身抗体的试剂在制备检测血管内皮损伤试剂盒的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020473A (en) * 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
EP1447089A3 (en) * 1998-09-09 2004-12-15 Scios Inc. Methods of treating hypertension and compositions for use therein
AU2003251397B2 (en) * 2002-06-05 2009-10-01 Genentech, Inc. Compositions and methods for liver growth and liver protection

Also Published As

Publication number Publication date
CN101454018A (zh) 2009-06-10
JP2009541207A (ja) 2009-11-26
US20070264259A1 (en) 2007-11-15
MX2008012276A (es) 2008-10-08
AU2007230580A1 (en) 2007-10-04
CA2647268A1 (en) 2007-10-04
RU2008142374A (ru) 2010-05-10
BRPI0709411A2 (pt) 2011-07-12
KR20080108570A (ko) 2008-12-15
US20080206243A1 (en) 2008-08-28
WO2007112364A1 (en) 2007-10-04
EP2015768A1 (en) 2009-01-21
IL194373A0 (en) 2011-08-01

Similar Documents

Publication Publication Date Title
MD3989972T2 (ro) Agonişti ai receptorului peptidei-1 asemănătoare glucagonului
EA200900048A1 (ru) Новые карбонилированные (аза)циклогексаны в качестве лигандов d3 рецептора дофамина
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
ATE447568T1 (de) Neue pyrinderivate
EA201000211A1 (ru) Способ модулирования рецептора gpr119, сопряженного с g-белком, и используемые при этом соединения
EA200970967A1 (ru) Оксадиазол замещенные производные индазола для применения в качестве агонистов сфингозин 1-фосфата (sip)
AR034637A1 (es) Anticuerpos que unen ligandos de osteoprotegerina (opgl)
EA200702363A1 (ru) Новые лиганды гистамина h-рецептора и их терапевтические применения
ECSP10010439A (es) Antagonistas n,n-disustituidos de aminoalquilbifenilo de receptores d2 de prostaglandina
EA200970067A1 (ru) Агонисты ep2
PE20142114A1 (es) Polipeptidos de receptores de activina variantes, solos o en combinacion con quimioterapia, y sus usos
EA200801369A1 (ru) Способы трансдермального введения агониста рецептора индолсеротонина и трансдермальные лекарственные формы для применения этого способа
EP2061907A4 (en) TCL1 EXPRESSION IN CHRONIC LYMPHOCYTIC LEUKEMIA (LLC) REGULATED BY MIR-29 AND MIR-181
EP2526934A3 (en) Inhibitors of bruton's tyrosine kinase
CR10627A (es) Metodos terapeuticos para el tratamiento de trastornos oculares vasculares con antagonistas de dii4
CL2007000601A1 (es) Compuestos derivados de heterobiciclos pirazolicos, inhibidores de la actividad de proteina tiroxina quinasa; composicion farmaceutica que comprende dichos compuestos; y uso de los compuestos en el tratamiento de una enfermedad hiperproliferativa.
EA200802213A1 (ru) Способы лечения заболеваний крови
CL2007002167A1 (es) Compuestos derivados de indol, antagonistas iap; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de cancer.
EA200870185A1 (ru) Комбинации ингибиторов ang2 и vegf
EA200800160A1 (ru) Композиты восстановленной ионной жидкостью целлюлозы в качестве матриц твёрдых подложек
EA201001402A1 (ru) Фармацевтические растворы, способ получения и терапевтическое применение
TW200744568A (en) Epinephrine dosing regimens
EA201000702A1 (ru) Некоторые производные 2-пиразинона и их применение в качестве ингибиторов нейтрофильной эластазы
EA200970274A1 (ru) Способы введения гипогликемических средств с длительным действием
DE602006018713D1 (de) Als agonisten für den nikotinischen acetylcholinrezeptor geeignete azabicycloalkanderivate

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application